Abstract
No animal model exists for the in vivo growth of Hodgkin's‐lymphoma‐derived cells. Neither unmanipulated Hodgkin's‐disease(HD)‐derived cell lines nor primary biopsy tissue could be grown in nude mice. Since the severe combined immunodeficient (SCID) mouse has been reported to be a better recipient for transplanted human lymphatic tissue than the nude mouse, we tested whether SCID mice provide suitable conditions for the in vivo growth of HD cell lines. Tumorigenicity of HD cells was tested in untreated and pre‐treated SCID mice and in another combined immunodeficient mouse strain, beige/nude/X‐linked immunodeficient (BNX) mouse. SCID mice supported in vivo growth of the 6 HD cell lines tested (L428, L540, L591, DEV, HD‐LM2, KM‐H2). Only one of the 6 lines (DEV) was tumorigenic in BNX mice. No HD cell line proliferated in T‐cell‐deficient nude mice. Thus, in vivo growth of HD cell lines appeared to be related to the degree of host immunodeficiency. Additional growth supportive treatments such as fibrosarcoma co‐transplantation, intraperitoneal mineral oil injection or immunosuppressive pre‐treatment (anti‐asialo‐GMI ‐antibody injection) permitted growth of 3 additional HD cell lines in BNX mice. The immunophenotype and karyotype of explanted graft cells were identical to the original cell lines. Our experiments describe an effective and reproducible xenograft model for growth of Hodgkin's‐disease‐derived cell lines. This may be of value for elucidating the growth characteristics of Hodgkin's‐lymphoma‐derived cells as well as for testing new therapeutic regimens. © 1992 Wiley‐Liss, Inc.